portfolio detail IsoPlexis

Venture Portfolio

IsoPlexis

CEO:
Sean Mackay

About:
IsoPlexis has a proprietary single cell multiplexing immunoassay and software suite that provides in-depth biological characterization of important immune and cancer cell subsets among heterogeneous populations. The tool enables discovery of novel biomarkers and accurate testing of molecules for clinical activity against these heterogeneous subsets.

Website:
www.isoplexis.com

CI Representative:
Daniel Wagner
Managing Director, Investments

back to portfolio